Lead Sponsor

Novartis Pharmaceuticals

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

No

•Males and Females aged ≥ 18 years (≥ 12 years in PART C) with PVNS or GCTTS with, at least, one measurable site of disease on MRI.
•Patients expected to get surgery (PART A of study only).
•Vital signs within the ranges: systolic blood pressure 80-150 mmHg , diastolic blood pressure 50-100 mmHg, pulse rate 40-100 bpm, oral body temperature 35.0-37.5°C.
•Patients with normal level of serum ionized calcium and phosphate.
•Women of child-bearing potential must use highly effective contraception during the study and for 84 days after the study drug infusion.

•Patients with major surgery less than 3 months prior to start study drug or who have still side effects of such therapy.
•Presence of systemic illness precluding definitive surgery or increasing the risk to patients due to potential immunosuppression.
•Use previously of intra-articular treatment within 4 weeks prior dosing.
•Patients with dermal change indicative of lymphedema or phlebolymphedema. disease.
•Patients with elevated troponin T and/or CK levels (\> 1.5 x ULN for the laboratory) or with history of myositis, rhabdomyolysis or other myopathic disease.
•Patients receiving immunosuppressive treatment as well as corticosteroids which cannot be discontinued at least 4 weeks before dosing.
•Patients engaged in a resistance exercise training program.
•Patients with pacemakers or any metallic objects as exclusion for MRI
•Patients with concomitant disease know to get influence on bone metabolism
•Patients who have history of drug or alcohol abuse within 12 months prior study dosing.
•Pregnant or nursing (lactating) women.

Related studies

NCT03069469 · Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, and more

NCT05349643 · Pigmented Villonodular Synovitis, TGCT, and more

NCT04731675 · Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS)

NCT02371369 · Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, and more

NCT02471716 · Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)